WO2009112609A1 - Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables - Google Patents
Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables Download PDFInfo
- Publication number
- WO2009112609A1 WO2009112609A1 PCT/ES2009/000121 ES2009000121W WO2009112609A1 WO 2009112609 A1 WO2009112609 A1 WO 2009112609A1 ES 2009000121 W ES2009000121 W ES 2009000121W WO 2009112609 A1 WO2009112609 A1 WO 2009112609A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- 4pba
- disease
- alzheimer
- treatment
- pharmaceutically acceptable
- Prior art date
Links
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 150000003839 salts Chemical class 0.000 title claims description 32
- 229950009215 phenylbutanoic acid Drugs 0.000 title abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000001939 inductive effect Effects 0.000 claims description 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 11
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 11
- OBKXEAXTFZPCHS-UHFFFAOYSA-M 4-phenylbutyrate Chemical compound [O-]C(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-M 0.000 claims description 10
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 159000000000 sodium salts Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 claims description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical group C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 229960005228 clioquinol Drugs 0.000 claims description 3
- RBXVOQPAMPBADW-UHFFFAOYSA-N nitrous acid;phenol Chemical class ON=O.OC1=CC=CC=C1 RBXVOQPAMPBADW-UHFFFAOYSA-N 0.000 claims description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 2
- 102100021496 Insulin-degrading enzyme Human genes 0.000 claims description 2
- 102100028782 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 49
- 102000004169 proteins and genes Human genes 0.000 abstract description 40
- 210000002472 endoplasmic reticulum Anatomy 0.000 abstract description 20
- 206010012289 Dementia Diseases 0.000 abstract description 18
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 abstract description 14
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 abstract description 14
- 101150112743 HSPA5 gene Proteins 0.000 abstract description 14
- 108010033040 Histones Proteins 0.000 abstract description 14
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 abstract description 14
- 101150028578 grp78 gene Proteins 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 230000007246 mechanism Effects 0.000 abstract description 12
- 208000010877 cognitive disease Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 108700019745 Disks Large Homolog 4 Proteins 0.000 abstract description 9
- 102000047174 Disks Large Homolog 4 Human genes 0.000 abstract description 9
- 102000006947 Histones Human genes 0.000 abstract description 9
- 101150069842 dlg4 gene Proteins 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 6
- 108010077544 Chromatin Proteins 0.000 abstract description 5
- 241001529936 Murinae Species 0.000 abstract description 5
- 210000003483 chromatin Anatomy 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 230000003956 synaptic plasticity Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000001243 protein synthesis Methods 0.000 abstract description 3
- 230000014616 translation Effects 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract 2
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 230000006196 deacetylation Effects 0.000 abstract 1
- 238000003381 deacetylation reaction Methods 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 description 58
- 241000699660 Mus musculus Species 0.000 description 55
- 241000699670 Mus sp. Species 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 102000013498 tau Proteins Human genes 0.000 description 24
- 108010026424 tau Proteins Proteins 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 14
- 210000001320 hippocampus Anatomy 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 13
- 230000035882 stress Effects 0.000 description 13
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000004770 neurodegeneration Effects 0.000 description 10
- 230000013016 learning Effects 0.000 description 9
- 230000015654 memory Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 238000012347 Morris Water Maze Methods 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 238000006640 acetylation reaction Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006195 histone acetylation Effects 0.000 description 6
- 230000006386 memory function Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000004906 unfolded protein response Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102000003678 AMPA Receptors Human genes 0.000 description 5
- 108090000078 AMPA Receptors Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 108010017007 glucose-regulated proteins Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- -1 forscolin Chemical compound 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000012846 protein folding Effects 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 102100039328 Endoplasmin Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 102000016227 Protein disulphide isomerases Human genes 0.000 description 2
- 108050004742 Protein disulphide isomerases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004637 cellular stress Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 230000027928 long-term synaptic potentiation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000007996 neuronal plasticity Effects 0.000 description 2
- 230000003950 pathogenic mechanism Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003660 reticulum Anatomy 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000003976 synaptic dysfunction Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000030954 urea cycle disease Diseases 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NFFHADOBVLBXJN-UHFFFAOYSA-N 4-phenylbutanoic acid Chemical compound OC(=O)CCCC1=CC=CC=C1.OC(=O)CCCC1=CC=CC=C1 NFFHADOBVLBXJN-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 102000038624 GSKs Human genes 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101100480715 Mus musculus Mapt gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940057372 buphenyl Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 239000003695 memory enhancer Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000005949 negative regulation of histone deacetylation Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000010831 regulation of synaptic plasticity Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
Definitions
- the present invention falls within the field of biotechnology applied to the medical-pharmaceutical sector for the treatment of cognitive disorders in dementias that occur with taupatias, and especially Alzheimer's.
- the present invention provides a new treatment for said diseases based on the use of 4PBA.
- AD Alzheimer's disease
- Alzheimer's disease is related to deposits of aggregate proteins: intracellular aggregates of phosphorylated tau in the neurofibrillary tangles and extracellular aggregates of ⁇ 3-amyloid (A ⁇ ) in the senile plaques. Therefore, Alzheimer's disease is a very representative example of diseases related to abnormal protein folding (Selkoe 2004).
- the endoplasmic reticulum (ER) is a site of particular importance in the process of quality control of processes related to proteins, since it regulates the synthesis, folding and trafficking of proteins in the body.
- the continuous production of proteins requires strict maintenance of quality control, which is carried out in the ER.
- ER does not always work with adequate accuracy and poorly folded proteins can accumulate inside. This situation may occur because there are proteins that are difficult to fold, such as those responsible for Alzheimer's disease, and also because the proteins are synthesized with faster than the ER can double them. This leads to a situation of "stress" of the ER.
- the sensors are activated and begin to deliver a series of signals aimed at stopping the synthesis of most of the proteins, and on the other hand to regulate the rate of doubling, so that it is possible to correctly bend all the proteins and ultimately recover the RE from your stress.
- RE stress is a key event when it comes to triggering and mediating neuronal death in Alzheimer's disease.
- Several types of cellular stress can cause the accumulation of abnormally folded proteins in the ER lumen, triggering this stress situation activating protein quality control mechanisms to prevent their toxic actions (or the response to known unfolding proteins by its acronym in English UPR "Unfolded Protein Response”).
- the activation of the UPR control mechanism produces a general reduction in protein synthesis, greater protein degradation and increasing the transcription of genes that encode molecular companions residing in the ER, such as glucose-regulated proteins (GRPs) GRP78 / Bip and GRP94, together with the protein disulphide isomerase (PDI), to facilitate protein folding (Kozutsumi et al., 1998).
- GRPs glucose-regulated proteins
- PDI protein disulphide isomerase
- the UPR is not able to resolve the stress of the ER that neuronal cells are experiencing, it is very possible that a progression of the disease will be achieved, triggering the apoptosis of neurons. Such would be the situation of the most common and devastating neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's disease, which are characterized by the accumulation and aggregation of unfolded proteins. Therefore, it is not surprising that many researchers have found evidence that under these extreme conditions the UPR is also activated. In this case this activation ends up doing more damage than benefit; The initial response is protective, but the final response is destructive.
- 4PBA is a low molecular weight fatty acid whose use has been approved in clinical practice as an ammonia sequestrant in children suffering from urea cycle disorders (Maestri et al., 1996) and in the treatment of sickle cell anemia and thalassemia due to its ability to activate transcription of fetal hemoglobulin (Dover et al., 1994; Collins et al., 1995). Its beneficial effect has also been documented in patients with Spinal Muscular Atrophy (Mercuri E, et al. 2004; Mercuri E, et al. 2007).
- 4PBA can act as a chemical companion by reversing the processes of abnormal localization and / or aggregation of proteins associated with human diseases (Rubenstein and Zeitlin, 2000; Kubota et al., 2006). Likewise, 4PBA can play a protective role in certain diseases associated with the neuroinflammatory response such as multiple sclerosis and ischemia (Dasgupta et al., 2003; Qi et al., 2004). The medical literature also cites its beneficial effects on polyglutamine toxicity (Steffan et al., 2001).
- the patent WO99 / 026657 protects the use of inducible nitric oxide synthase (iNOS) inhibitor compounds.
- iNOS inducible nitric oxide synthase
- the reference to PBA is made marginally in the context of a ratio of iNOS inhibitor compounds (lovastatin, forscolin, mevastatin, etc.).
- lovastatin, forscolin, mevastatin, etc. there is no experiment aimed at demonstrating the beneficial effect of PBA in a contrasted model of AD.
- tau phosphorylation is an integral component of neural machinery, so that a lack of regulation of this function leads to a deterioration of memory in the development of diseases such as Alzheimer's (Arendt et al., 2003; Ikeda et al., 2007).
- Histone acetylation mediates the regulation of gene transcription via chromatin modification, and therefore has recently been implicated in synaptic plasticity.
- the administration of 4PBA has been shown to increase histone acetylation in a murine model expressing amyotrophic lateral sclerosis (Petri S, et al., 2006). Consequently, it He speculated that 4PBA, by inhibiting histone deacetylase, can induce a transcriptional modification that leads to the activation of neuronal plasticity genes. Andreassi et al. (2004) directly related the administration of 4PBA with the increase in the complete expression of genes whose loss is responsible for Spinal Muscular Atrophy.
- Gene transcription requires the activation of transcription factors, but also the induction of dynamic changes in the chromatin organization that directs gene expression. Hypeacetylation of histones releases histones from their binding with chromatin, which has subsequent effects on gene transcription processes (Lea and Randolph, 1998) and protein synthesis. It has been shown that the synthesis of RNA and "de novo" proteins are necessary for the long-term memory formation process in several species of vertebrate and invertebrate animals, and that the formation of new synaptic connections will probably mediate ( Tully et al., 2003).
- the histone acetylation process controls the transcription of the genes necessary for memory consolidation and long-term synaptic potentiation (LTP) (Bailey et al., 2004, Levenson and Sweatt 2005; Fischer et al., 2007 ).
- LTP long-term synaptic potentiation
- HAT histone acetyltransferase
- HDAC histone deacetylase
- Some studies have shown that gene transcription has been deregulated in some brain regions in association with disease progression and supports the notion of a mechanism for disruption of RNA transcription in some degenerative disorders (Anderson et al., 2007).
- the GIuRl subunit of the AMPA receptor and PSD95 are postsynaptic markers of crucial importance in synapse formation and function.
- the postsynaptic deficits of PSD95 and GIuRl found in the brains of patients affected by Alzheimer's disease and in the brains of Tg2576 transgenic mice can contribute to synaptic dysfunction and cognitive function deficits (Almeida et al., 2005).
- Several studies have already outlined the spectrum of genes altered by 4PBA that prevent neurotoxicity in different experimental models (Chang and Min, 2002; Kang et al., 2002; Ryu et al., 2005).
- the pathophysiology of many degenerative disorders such as Alzheimer's disease, and also neuroprotection, probably comprise numerous mechanisms.
- these pathogenic mechanisms mainly include the aggregation and deposition of AJ3 with the development of plaques, hyperphosphorylation of tau with the formation of clews, neurovascular dysfunction, and other mechanisms such as alterations of the cell cycle , inflammatory processes, oxidative stress and mitochondrial dysfunction.
- the central hypothesis about the cause of Alzheimer's disease is the amyloid cascade hypothesis.
- Alzheimer's disease will be the great challenge of socio-health planning for the next 50 years. Since there is no effective treatment for Alzheimer's disease, this invention describes the ability of 4PBA, through its multiple mechanisms, to reverse the deterioration in the learning process and memory function characteristic of Alzheimer's disease in a model murine
- Fischer et al in 2007 is not a representative model of Alzheimer's disease, since it does not reproduce the pathogenic mechanisms related to human beta-amyloid protein or aberrant phosphorylation of tau. In particular, it only represents the deficient expression of the p25 protein, a truncated form of p35, which is a regulatory subunit of the cyclin-5 dependent kinase (CDK5).
- CDK5 cyclin-5 dependent kinase
- the inventors of the present invention using a transgenic mouse model agreed and validated for Alzheimer's disease, ie Tg2576, which expresses a variety of human beta-amyloid precursor protein (APP) related to the disease of the Alzheimer's have surprisingly found that 4-phenylbutyrate is effective in the treatment of Alzheimer's disease.
- the inventors have been able to demonstrate that clinical symptoms are improved as well as memory acquisition and retention, and most importantly, they have also shown that after administration of 4PBA, hyperphosphorylated tau levels are reduced.
- the present invention describes the potentially beneficial role of 4PBA in Alzheimer's type amnesia.
- the results obtained suggest that the effect of 4PBA is likely to be mediated, on the one hand by the protection that confers cells against the effects of endoplasmic reticulum stress by increasing levels of molecular companions and inducing tau dephosphorylation, and by another part by increasing the acetylation of histone H4 that induces the expression of synaptic markers, which in turn leads to the recovery of long-term spatial memory.
- H4 in the cerebral cortices of Tg2576 transgenic mice could be related to a very densely packed chromatin structure that would correspond to transcriptional repression.
- the present invention relates to the use of 4PBA or a pharmaceutically acceptable salt thereof for the prevention and / or treatment of Alzheimer's disease.
- the present invention relates to the use of 4PBA or a pharmaceutically acceptable salt thereof for obtaining a medicament for the prevention and / or treatment of Alzheimer's disease.
- the present invention describes a method for preventing or treating Alzheimer's disease, which comprises the administration of a pharmaceutically acceptable amount of 4PBA or a pharmaceutically acceptable salt thereof to a subject in need of such prevention or treatment.
- 4PBA used here also refers to those metabolites or compounds resulting from its metabolization in the body.
- the embodiments of the present invention related to the different therapeutic uses of this compound also comprise the use of its metabolite, that is, phenylacetate.
- the present invention relates to 4PBA or any of its pharmaceutically acceptable salts, or of a composition comprising 4PBA or any of its pharmaceutically acceptable salts, for use in the prevention or treatment of dementias that occur with taupathy, and more particularly for use in the prevention or treatment of cognitive disorders in said dementias.
- the invention also relates to the use of 4PBA or any of its pharmaceutically acceptable salts, or of a composition comprising 4PBA or any of its pharmaceutically acceptable salts, in the preparation of a medicament for prevention or treatment of dementias that occur with taupathy, and in particular of the cognitive disorders associated with these dementias.
- the invention particularly relates to the sodium salt of 4PBA for use in the prevention or treatment of dementias that occur with taupathy.
- 4PBA is 4-phenyl-butyric acid (4-phenyl-butyrate), a commercially available product, which can be obtained for example from SIGMA-ALDRICH (Product No.: P21005); It has registration number CAS 1821-12-1; Its chemical formula is C 6 H 5 (CH 2 ) 3 COOH.
- the sodium salt of 4PBA is also a commercially available product, which can be obtained for example from BIOMOL International LP (Palatine House, Matford Court, Starbucks EX2 8NL, UK; Catalog No. EI320); It has registration number CAS 1716-12-7; Its chemical formula is C 6 H 5 (CH 2 J 3 COONa; and its structural formula is:
- this compound can be obtained by known methods.
- Buphenyl ® and Ammonaps ® are trademarks of sodium phenyl butyrate compositions, authorized by the FDA and EMEA respectively, for the treatment of urea cycle disorders. It can also be found under the trademark TriButyrate ® (Triple Crown America).
- pharmaceutically acceptable means that the compound or combination of compounds must be compatible with the rest of the ingredients in a formulation, and not deleterious to the subject or patient who receives it.
- 4PBA salts are those in which the counter-ion is pharmaceutically acceptable.
- composition comprising 4PBA or a pharmaceutically acceptable salt thereof is a pharmaceutical composition, which also comprises a pharmaceutically acceptable carrier or excipient.
- the pharmaceutically acceptable salts mentioned above are considered to comprise the active non-toxic forms that 4PBA can form.
- Pharmaceutically acceptable salts can be conveniently obtained by treating the acid form of 4PBA with the appropriate cations.
- Appropriate basic salts include those formed with organic cations such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and those formed with metal cations such as aluminum, calcium, lithium, magnesium, potassium, sodium and zinc.
- salt forms can be converted into their free forms by treatment with an appropriate acid.
- salts is also intended to include the hydrates and solvates that 4PBA can form, such as, for example, alcoholates such as methanolates or ethanolates.
- solvate refers to those crystalline forms of 4PBA that comprise both stoichiometric and non-stoichiometric amounts of solvent. Since water is a solvent, solvates also include hydrates.
- pseudopolymorph is a synonym for solvate when it refers to crystalline polymorphic forms that have solvent molecules incorporated into their laminar structures. Hydrates and Alcoholates such as methanolates or ethanolates are examples of this type of solvates.
- prevention refers to the act of "preventing”, understood to prevent the occurrence, existence, or alternatively delaying, the occurrence or recurrence of a disease, disorder or condition to which said term applies, or of one or several of the symptoms associated with the disease, disorder or condition.
- treatment refers to the act of "treating”, a term that in turn is understood as reversing, alleviating or inhibiting the progression of the disease, disorder or condition to which the term applies, or of one or more of the symptoms of said disease, disorder or condition.
- “Dementias that occur with taupathy” refers to neurodegenerative diseases in which there is an alteration of the metabolism of the Tau protein and in which one of its most relevant symptoms or consequences is the appearance of cognitive disorders.
- the use of 4PBA or its salts is useful for the prevention or treatment of cognitive disorders associated with such dementias.
- the invention relates to the prevention or treatment of diseases such as Alzheimer's, frontotemporal dementia, progressive supranuclear paralysis, corticobasal degeneration, Pick's disease, Lewy body dementia, dementia with argyrophilic grains, Niemann-Pick type C disease, or pugilistic dementia.
- diseases such as Alzheimer's, frontotemporal dementia, progressive supranuclear paralysis, corticobasal degeneration, Pick's disease, Lewy body dementia, dementia with argyrophilic grains, Niemann-Pick type C disease, or pugilistic dementia.
- a more preferred embodiment of the present invention is the use of the sodium salt of 4PBA in the manufacture of a medicament for the treatment of the described diseases.
- the invention in another aspect relates to a composition comprising 4PBA or any of its pharmaceutically acceptable salts for use in the prevention or treatment of dementias that occur with taupathy, and in particular of the cognitive disorders associated with them.
- the composition comprises the sodium salt of 4PBA.
- a particular embodiment concerns a pharmaceutical composition comprising a pharmaceutically acceptable salt of 4PBA and a pharmaceutically acceptable carrier for use in the prevention and treatment of Alzheimer's disease.
- So another embodiment of the present invention to enhance its healing effect is a combination that It comprises 4PBA and / or any of its pharmaceutically acceptable salts as the first active ingredient together with a second active ingredient agent that is an inducing or facilitating agent for the clearance of cerebral ⁇ -amyloid deposits.
- a more preferred embodiment uses metal chelating agents, catabolizing enzymes of the soluble form of the ⁇ -amyloid peptide, cerebrolysin or nitrophenols as the inducing agent for said deposits.
- Another embodiment of the present invention offers an acceptable pharmaceutical combination comprising 4PBA or one of its pharmaceutical salts as the first active ingredient, a second active ingredient agent is an inducer or a facilitating agent for the clearance of ⁇ -amyloid deposits in the brain, and a pharmaceutically acceptable vehicle.
- a more preferred embodiment uses as a inducing agent for the clearance of said deposits, metal chelating agents, catabolizing enzymes of the soluble form of the ⁇ -amyloid peptide, cerebrolysin or nitrophenols.
- a more preferred embodiment is the use of clioquinol, cerebrolysin, or 2,4-dinitrophenol or 3-nitrophenol as a clearing agent.
- a more preferred embodiment is the use of clioquinol, cerebrolysin, IDE insulin degrading enzyme or neprilysin, or 2,4,4-dinitrophenol or 3-nitrophenol as a deposit clearance inducing agent.
- Another embodiment of the invention is therefore the use of a product containing 4PBA and / or any of its pharmaceutically acceptable salts as the first active ingredient, and a second active ingredient that is an inducing or facilitating agent for the clearance of ⁇ - deposits.
- cerebral amyloid as a combined preparation for simultaneous use in the prevention and / or treatment of cognitive disorders in dementias that occur with taupathy.
- this combined preparation is designed for a separate use of both active ingredients, and yet another embodiment is that it is for sequential use.
- the two active components or ingredients of the pharmaceutical combination of the invention may be part of the same unit pharmaceutical formulation; or forming part of separate pharmaceutical formulations for co-administration of the two active components or ingredients but forming part of the same therapeutic regimen.
- the two components are administered in separate formulations, they do not need to be administered at the same time, although it could be done if desired.
- the invention relates to a product or kit comprising a pharmaceutical combination comprising 4PBA and / or any of its pharmaceutically acceptable salts together with an inducing or facilitating agent for the clearance of cerebral ⁇ -amyloid deposits, in any of the specified embodiments.
- the invention relates to said pharmaceutical combination or kit comprising said pharmaceutical combination for use in the prevention or treatment of dementias that occur with taupathy, and particularly associated cognitive disorders.
- Said combination or kit is useful for the preparation of a medicament for the prevention of said dementias, in particular any of those specified above, and more particularly for Alzheimer's disease.
- the invention also relates to a method for prevention or treatment of dementias that occur with taupathy, and particularly of the cognitive disorders associated therewith, which comprises administering to a subject in need of such prevention and / or treatment a pharmaceutically effective amount of 4PBA or any of its pharmaceutically acceptable salts, or of a composition comprising 4PBA or any of its pharmaceutically acceptable salts, or one of a pharmaceutical combination comprising 4PBA and / or any of its pharmaceutically acceptable salts together with an inducing or facilitating agent for the clearance of cerebral ⁇ -amyloid deposits.
- pharmaceutically effective amount refers to an amount of compound or combination of active compounds that is effective in the treatment of the disease, which improves, attenuates or eliminates one or more of its symptoms; or prevents or delays the appearance of one or more symptoms of the disease.
- the dose of active substances of the present invention depends on each individual case and, usually, has to be adapted to the individual conditions of the case for optimal effect. . Therefore, it depends, of course, on the frequency of administration and the potency and duration of the action of the compound used in each case for therapy or prophylaxis, but also on the nature and severity of the disease and symptoms, and on sex. , age, weight, co-medication and the responsibility of the human or animal being treated and whether the therapy is acute or prophylactic.
- the therapeutically effective amount of 4PBA and / or its pharmaceutically acceptable salts should be in the following ranges, from 1 mg to 200 g per day, from 2 mg to 150 g per day, from 5 mg to 100 g per day, from 10 mg to 75 g per day, from 20 mg to 75 g per day, from 50 mg to 75 g per day, from 0.1 g to 75 g per day, from 0.2 g up to 75 g per day, from 0.5 to 75 g per day, from 1 g to 50 g per day and from 5 g to 50 g per day.
- subject means an animal, in particular a mammal such as primates, dogs, cats, bovine animals, horses, sheep and humans. It applies particularly to human mammals of both sexes.
- a preferred form of administration of the medicament preparation containing 4PBA for the uses described above is in tablets containing its sodium salt.
- the pharmaceutical preparation of these tablets may comprise excipients such as microcrystalline cellulose, magnesium stearate or colloidal silicon dioxide.
- Another preferred form of administration is a powder containing the 4PBA sodium salt and an excipient to be dissolved in water.
- the pharmaceutical preparation of this powder may comprise excipients such as calcium stearate or colloidal silicon dioxide.
- Figure IA Latency times of transgenic mice treated with 4PBA and with saline, with respect to non-transgenic mice, on different days of measurement of a Morris test in the visible platform phase.
- Figure IB Latency times of transgenic mice treated with 4PBA and saline, with respect to non-transgenic mice, on different days of measuring a Morris test in the invisible platform phase.
- Figure IC Time of permanence in the correct quadrant of the transgenic mice treated with 4PBA and with saline, with respect to non-transgenic mice, on different days of measurement of a Morris test.
- Figure 2A Levels of derivatives of peptides A ⁇ 42 and A ⁇ 40 in bark extract of transgenic mice treated with 4PBA and with saline.
- Figure 2B Plating of plaques formed by accumulation of the A ⁇ peptide in the brain of transgenic mice treated with 4PBA and with saline compared to non-transgenic mice.
- Figure 3A Relationship between phosphorylated tau levels with respect to normal protein in transgenic mice treated with 4PBA and saline, with respect to non-transgenic mice.
- Figure 3B Relationship between levels of phosphorylated GSK3 (inactive form) with respect to unphosphorylated protein (active form) in transgenic mice treated with 4PBA and saline, with respect to non-transgenic mice.
- Figure 4 GRP78 expression levels in hippocampal extracts of transgenic mice treated with 4PBA and saline, compared to non-transgenic mice.
- FIG. 5 Levels of Histones 4 (AcH4) and histone 3 (AcH3) acetylated in bark extracts of transgenic mice treated with 4PBA and saline, compared to non-transgenic mice.
- Figure 6 GIuRl, PSD95 and MAP-2 protein expression levels in membrane-enriched protein extracts obtained from the hippocampus of transgenic mice treated with 4PBA and saline, with respect to non-transgenic mice.
- Tg2576 transgenic mice with Alzheimer's disease that express the human isoform 695-aa of APP containing the Swedish double mutation APPswe [(APP695) Lys670 ⁇ Asn, Met671 ⁇ Leu] triggered by a hamster cryonic promoter.
- the content of the A ⁇ peptide in the brain accumulates exponentially between 7 and 12 months of age, and the mice so manipulated showed deterioration of the function of memory when they were subjected to the Morris water maze test when they reached ages between 12 and 15 months.
- the 16-month-old Tg2576 mouse females were treated once daily intraperitoneally with 200 mg / kg 4PBA or their vehicle for 5 weeks.
- a solution of 4PBA was prepared by titrating equimolecular amounts of 4-phenylbutyric acid (Sigma) and sodium hydroxide with a pH: 7.4.
- a control group a group of non-genetically altered mice, normal mice, of similar strains and age was used. All clinical trial procedures were performed according to European and Spanish legislation (86/609 / EEC; RD1201 / 2005).
- the labyrinth consisted of a circular pool full of water at 20 0 C. The mice received prior training in a pool with a visible platform for three consecutive days (8 tests / day) being able to swim to an elevated platform by above water level.
- the hidden platform training lasted 9 consecutive days (4 tests / day) during which the mice were allowed 60 seconds to find the submerged platform 1 cm below the water surface. The mice that found it impossible to reach the platform were guided to it. All animals were allowed a rest on the 20-second platform and then removed from it to return them to their cages. At the beginning of the 4 th, 1st and final day of the test, a pre - test during which the pool deck was removed and allowed the mice search for 60 seconds was performed. All attempts were monitored with an HVS camera and the Watermaze program to analyze the escape latencies and the percentage of occupancy time of each quadrant of the pool during the previous tests (with the Ethovision program, Wageningen, The Netherlands). Mice that were not able to learn to locate the visible platform or mice that exhibited abnormal swimming patterns or were floating persistently were excluded from the analyzes.
- mice were subjected to a previous test during which they were made to swim in the pool from which the platform had been removed for 15 seconds.
- a measure of retention memory is the percentage of 15 seconds of swimming in the quadrant in which the platform was during training sessions (target quadrant).
- the percentage of time that the vehicle-treated transgenic mice spent in the target quadrant was significantly less than that of the control group mice.
- the amount of time that the transgenic mice treated with 4PBA spent in said quadrant did not differ from that of the mice of the same age control group (Fig. IC). Although the differences were evident in the invisible platform test, the escape latencies did not differ significantly during the first training tests with visible platform (Fig. IA).
- mice were sacrificed 24 hours after they performed the last test in the Morris water maze.
- the cortex and hippocampus were dissected and used to perform biochemical analyzes.
- the levels of AJ340 and AJ342 in the cerebral cortex were then determined by a sandwich ELISA.
- extracts of frontal cerebral cortex were obtained from the mice and homogenized in a cold lysis buffer with protease inhibitors (0.2 M NaCl, 0.1 M HEPES, 10% glycerol, 200 mM NaF, 2 mM Na4P2O7, 5 mM EDTA, 1 mM EGTA, 2 mM DTT, 0.5 mM PMSF, 1 mM Na 3 VO 4 , 1 mM benzamidine, 10 ⁇ g / ml leupeptin, 400 U / ml aprotinin), and se were centrifuged at 14,000 xg 4 ° C for 20 min and aliquots of the supernatant stored at -80 0 C. were obtained the total protein concentration was obtained with the Bradford BioRad Bradford (BioRad Laboratories, Hercules, California) test.
- protease inhibitors 0.2 M NaCl, 0.1 M HEPES, 10% glycerol, 200 m
- Example 5 Pathological markers of Alzheimer's disease To investigate the changes that could explain the differences observed in the learning capacity of transgenic mice after treatment, phosphorylation levels of tau in the hippocampus extracted from mice were analyzed using AT8 , a phospho-specific antibody that recognizes hyperphosphorylated aberrant epitopes on Ser-202 / Thr-
- Fig. 3A The phosphorylation function of tau is regulated by several protein kinases and phosphatases. It has been shown that GSK3b participates in the pathological phosphorylation of tau. The levels of inactive GSK3b, phosphorylated in Ser 9, were measured and found to be higher in the hippocampi of transgenic mice treated with 4PBA when compared to mice treated with the vehicle, which would explain the reduction in phosphorylated form of tau observed in the treated mice ( Figure 3B).
- the next step of the investigation was to analyze the levels of the molecular companion resident in the GRP78 endoplasmic reticulum in the hippocampus of transgenic mice and bait brothers of the control group mice.
- GRP78 levels were found to be lower in the hippocampus of 16 month old transgenic mice when compared to those of mice of the same age.
- the GRP78 levels of transgenic mice treated with 4PBA did not differ from the levels of GRP78 found in non-transgenic mice, suggesting that the effect of 4PBA treatment may be due in part to an increase in the expression of the GRP78 levels (Fig. 4).
- Tg2576 16-month-old transgenic mice showed very low levels of H4 acetylation when compared with those of mice in the same age control group. Therefore, induction was found in acetylation of cortical histone 4 (H4) in transgenic mice that had been treated with 4PBA (Fig. 5).
- the GIuRl subunit of the AMPA receptor, PSD95 and MAP-2 are vitally important plasticity markers in the formation and function of the synapse.
- the microtubule association protein (MAP-2) is a protein located mainly in neuronal dendrites.
- the expression of MAP-2 coincides with the growth, branching and dendritic remodeling post-injury, suggesting that this protein plays a crucial role in plasticity.
- a quantitative analysis of MAP-2 was performed by Western Blott, and it was found that MAP-2 expression levels were significantly lower than those of the non-transgenic mouse (54.9 + 10.7) compared to non-transgenic mice (100.0 ⁇ 14.9) and partially restored after treatment with 4PBA. (77.7 ⁇ 11.6) (Fig. 6).
- Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GIuRl in synapses. Neurobiol Dis 20: 187-198.
- Kang HL Benzer S, Min KT (2002). Life extension in Drosophila by feeding a drug.
- Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response, Nat CeIl Biol 1, 479-485.
- Histone deacetylase inhibitors exhibit anti-inf lammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 321: 892-901. - Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J (1998). The presence of malfolded proteins in the endoplasmic reticulum sign the induction of glucose-regulated proteins. Nature 332: 462-464.
- ASKl is essential for endoplasmic reticulum stress -induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16: 1345-55.
- Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010550224A JP2011518119A (ja) | 2008-03-13 | 2009-03-06 | 4−フェニル酪酸(4pba)およびその医薬上許容し得る塩についての新規用途 |
AU2009224613A AU2009224613A1 (en) | 2008-03-13 | 2009-03-06 | Novel uses of sodium 4-phenylbutyrate (4 PBA) and the pharmaceutically acceptable salts thereof |
CN2009801183670A CN102036665A (zh) | 2008-03-13 | 2009-03-06 | 4-苯基丁酸钠(4pba)及其药学上可接受的盐的新颖用途 |
EP09719846A EP2272515A1 (en) | 2008-03-13 | 2009-03-06 | Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
CA2718463A CA2718463A1 (en) | 2008-03-13 | 2009-03-06 | Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts |
MX2010009933A MX2010009933A (es) | 2008-03-13 | 2009-03-06 | Nuevos usos del 4-fenilbutirato de sodio (4pba) y sus sales farmaceuticamente aceptables. |
BRPI0909745A BRPI0909745A2 (pt) | 2008-03-13 | 2009-03-06 | novos usos de 4-fenil butirato de sódio (4pba) e de seus sais farmaceuticamente aceitáveis |
US12/921,933 US20110027251A1 (en) | 2008-03-13 | 2009-03-06 | Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800736A ES2332687B1 (es) | 2008-03-13 | 2008-03-13 | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
ESP200800736 | 2008-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009112609A1 true WO2009112609A1 (es) | 2009-09-17 |
Family
ID=40691368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2009/000121 WO2009112609A1 (es) | 2008-03-13 | 2009-03-06 | Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110027251A1 (es) |
EP (1) | EP2272515A1 (es) |
JP (1) | JP2011518119A (es) |
CN (1) | CN102036665A (es) |
AU (1) | AU2009224613A1 (es) |
BR (1) | BRPI0909745A2 (es) |
CA (1) | CA2718463A1 (es) |
ES (1) | ES2332687B1 (es) |
MX (1) | MX2010009933A (es) |
RU (1) | RU2010138638A (es) |
WO (1) | WO2009112609A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101973868A (zh) * | 2010-11-12 | 2011-02-16 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅰ型结晶及其制备方法 |
CN102757334A (zh) * | 2012-07-30 | 2012-10-31 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅱ型晶体及其制备方法 |
JP2013523795A (ja) * | 2010-04-06 | 2013-06-17 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 植物のストレス耐性を増強させるための4−フェニル酪酸及び/又はその塩の使用 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2599479A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | 4-phenylbutyric acid for the treatment of alzheimer's disease |
US9480673B2 (en) | 2012-03-29 | 2016-11-01 | The Regents Of The University Of Colorado, A Body Corporate | Composition and method for treating neurodegenerative disease |
US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
WO2015006643A2 (en) * | 2013-07-12 | 2015-01-15 | Immuneering Corporation | Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition |
US11224668B2 (en) * | 2016-02-29 | 2022-01-18 | Neurovation Labs, Inc. | Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD |
WO2017160345A1 (en) | 2016-03-15 | 2017-09-21 | Acer Therapeutics Inc. | Palatable compositions including sodium phenylbutyrate and uses thereof |
WO2017159484A1 (ja) * | 2016-03-18 | 2017-09-21 | 学校法人同志社 | 2,4-ジアミノフェノール誘導体、及び、タウ及び/又はアミロイドβの凝集阻害剤 |
JP2019214546A (ja) * | 2018-06-11 | 2019-12-19 | 学校法人福岡大学 | 終末糖化産物生成抑制剤及び医薬組成物 |
JP2020083827A (ja) * | 2018-11-27 | 2020-06-04 | 国立研究開発法人農業・食品産業技術総合研究機構 | ケミカルシャペロンまたは神経細胞死の抑制剤 |
US20220119794A1 (en) * | 2018-12-27 | 2022-04-21 | Virginia Polytechnic Institute And State University | Chemically programmed neutrophils and uses thereof |
US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
US20240108593A1 (en) * | 2020-12-07 | 2024-04-04 | University Of Miami | Method of treating polyamine imbalance-related disorders |
CA3237768A1 (en) * | 2021-11-08 | 2023-05-11 | Amylyx Pharmaceuticals, Inc. | Combination of turso and sodium phenyl butyrate for the treatment of neurodegenerative diseases |
CN116099003A (zh) * | 2022-11-28 | 2023-05-12 | 核工业总医院 | 内质网应激抑制剂在放射性认知功能障碍药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
WO2002090534A1 (en) * | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
US20060074104A1 (en) * | 1998-03-06 | 2006-04-06 | Bush Ashley I | Use of clioquinol for the therapy of alzheimer's disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
PL188838B1 (pl) * | 1996-08-13 | 2005-04-29 | P N Gerolymatos Sa | Zastosowanie kliochinolu do wytwarzania środka farmaceutycznego i środek farmaceutyczny |
US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
EP1482962A4 (en) * | 2002-02-15 | 2009-12-23 | Sloan Kettering Inst Cancer | METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX) |
WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
-
2008
- 2008-03-13 ES ES200800736A patent/ES2332687B1/es not_active Withdrawn - After Issue
-
2009
- 2009-03-06 WO PCT/ES2009/000121 patent/WO2009112609A1/es active Application Filing
- 2009-03-06 MX MX2010009933A patent/MX2010009933A/es unknown
- 2009-03-06 EP EP09719846A patent/EP2272515A1/en not_active Withdrawn
- 2009-03-06 CN CN2009801183670A patent/CN102036665A/zh active Pending
- 2009-03-06 AU AU2009224613A patent/AU2009224613A1/en not_active Abandoned
- 2009-03-06 BR BRPI0909745A patent/BRPI0909745A2/pt not_active IP Right Cessation
- 2009-03-06 CA CA2718463A patent/CA2718463A1/en not_active Abandoned
- 2009-03-06 JP JP2010550224A patent/JP2011518119A/ja not_active Withdrawn
- 2009-03-06 RU RU2010138638/15A patent/RU2010138638A/ru not_active Application Discontinuation
- 2009-03-06 US US12/921,933 patent/US20110027251A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US20060074104A1 (en) * | 1998-03-06 | 2006-04-06 | Bush Ashley I | Use of clioquinol for the therapy of alzheimer's disease |
WO2002090534A1 (en) * | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
Non-Patent Citations (4)
Title |
---|
BLENNOW K ET AL: "Alzheimer's disease", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 368, no. 9533, 29 July 2006 (2006-07-29), pages 387 - 403, XP025094408, ISSN: 0140-6736, [retrieved on 20060729] * |
DE FELICE FERNANDA G ET AL: "Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: Implications for Alzheimer's therapy", FASEB JOURNAL, vol. 15, no. 7, May 2001 (2001-05-01), pages 1297 - 1299, XP007908887, ISSN: 0892-6638 * |
FINDEIS ET AL: "The role of amyloid beta peptide 42 in Alzheimer's disease", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 116, no. 2, 26 September 2007 (2007-09-26), pages 266 - 286, XP022272072, ISSN: 0163-7258 * |
SALLOWAY S ET AL: "Disease-modifying therapies in Alzheimer's disease", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 4, no. 2, 1 March 2008 (2008-03-01), pages 65 - 79, XP022613407, ISSN: 1552-5260, [retrieved on 20080220] * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013523795A (ja) * | 2010-04-06 | 2013-06-17 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 植物のストレス耐性を増強させるための4−フェニル酪酸及び/又はその塩の使用 |
CN101973868A (zh) * | 2010-11-12 | 2011-02-16 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅰ型结晶及其制备方法 |
CN101973868B (zh) * | 2010-11-12 | 2012-08-15 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅰ型结晶及其制备方法 |
CN102757334A (zh) * | 2012-07-30 | 2012-10-31 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅱ型晶体及其制备方法 |
CN102757334B (zh) * | 2012-07-30 | 2014-05-28 | 北京恒瑞康达医药科技发展有限公司 | 苯丁酸钠ⅱ型晶体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102036665A (zh) | 2011-04-27 |
RU2010138638A (ru) | 2012-04-20 |
BRPI0909745A2 (pt) | 2019-09-24 |
ES2332687A1 (es) | 2010-02-10 |
EP2272515A1 (en) | 2011-01-12 |
AU2009224613A1 (en) | 2009-09-17 |
CA2718463A1 (en) | 2009-09-17 |
MX2010009933A (es) | 2010-12-06 |
US20110027251A1 (en) | 2011-02-03 |
JP2011518119A (ja) | 2011-06-23 |
ES2332687B1 (es) | 2011-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2332687B1 (es) | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. | |
JP7365426B2 (ja) | 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 | |
Yang et al. | New role of silent information regulator 1 in cerebral ischemia | |
Parry et al. | Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure | |
US10966989B2 (en) | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders | |
Tian et al. | Minocycline alleviates sevoflurane-induced cognitive impairment in aged rats | |
US20120316247A1 (en) | Prevention and treatment of post-operative cognitive dysfunction (pocd) | |
WO2020222799A1 (en) | A method of treating mental, behavioral, cognitive disorders | |
WO2019205748A1 (zh) | 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用 | |
Zhang et al. | Montelukast ameliorates streptozotocin-induced cognitive impairment and neurotoxicity in mice | |
Wang et al. | Win55, 212-2 improves neural injury induced by HIV-1 glycoprotein 120 in rats by exciting CB2R | |
Zhang et al. | Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model | |
Wang et al. | Effects of curcumin on hippocampal Bax and Bcl-2 expression and cognitive function of a rat model of Alzheimer's disease*☆ | |
JP2022528748A (ja) | 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物 | |
Sarode et al. | Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury | |
KR20210102208A (ko) | 신경계 질환의 치료 | |
TWI465234B (zh) | Pipoxolan之新穎用途及基於此新穎用途的藥學組合物 | |
Zhong et al. | Tianma-Gouteng pair ameliorates the cognitive deficits on two transgenic mouse models of Alzheimer's disease | |
WO2017178685A1 (es) | Tratamiento de enfermedades neurodegenerativas | |
Dayuan et al. | Effect of α-mangostin on amyotrophic lateral sclerosis and its mechanism | |
Nakajima et al. | Effects of Nobiletin in Animal Models of Cognitive Impairment: Current Insights and Future Perspectives | |
WO2014204956A1 (en) | Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage | |
ES2357934B2 (es) | Uso de un espirolido analogos y derivados para el tratamiento y/o la prevencion de patologias relacionadas con las proteinas tau y b-amiloide. | |
JP2023531869A (ja) | 神経保護を誘導するための化合物及び組成物 | |
CA3125142A1 (en) | Domperidone antineurodegenerative combinations and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980118367.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09719846 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/009933 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2718463 Country of ref document: CA Ref document number: 2010550224 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009224613 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3401/KOLNP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12921933 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2009224613 Country of ref document: AU Date of ref document: 20090306 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009719846 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010138638 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0909745 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100913 |